G. Andrei and D. B. Gammon, Cidofovir Resistance in Vaccinia Virus Is Linked to Diminished Virulence in Mice, Journal of Virology, vol.80, issue.19, pp.9391-401, 2006.
DOI : 10.1128/JVI.00605-06

C. Bardou and C. Borie, Peptide Aptamers for Small Molecule Drug Discovery, Methods Mol Biol, vol.535, pp.373-88, 2009.
DOI : 10.1007/978-1-59745-557-2_21
URL : https://hal.archives-ouvertes.fr/hal-00416047

P. Berche, The threat of smallpox and bioterrorism, Trends in Microbiology, vol.9, issue.1, pp.15-23, 2001.
DOI : 10.1016/S0966-842X(00)01855-2

M. B. Bickle and E. Dusserre, Selection and characterization of large collections of peptide aptamers through optimized yeast two-hybrid procedures, Nature Protocols, vol.313, issue.3, pp.1066-91, 2006.
DOI : 10.1038/nprot.2006.32

R. Blasco and B. Moss, Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000- Dalton outer envelope protein, J Virol, vol.65, issue.11, pp.5910-5930, 1991.

K. A. Boyle and L. Arps, Biochemical and Genetic Analysis of the Vaccinia Virus D5 Protein: Multimerization-Dependent ATPase Activity Is Required To Support Viral DNA Replication, Journal of Virology, vol.81, issue.2, pp.844-59, 2007.
DOI : 10.1128/JVI.02217-06

M. Bray and M. Martinez, Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir, Antiviral Research, vol.54, issue.3, pp.129-171, 2002.
DOI : 10.1016/S0166-3542(01)00220-0

M. Bray and M. Martinez, Cidofovir Protects Mice against Lethal Aerosol or Intranasal Cowpox Virus Challenge, The Journal of Infectious Diseases, vol.181, issue.1, pp.10-19, 2000.
DOI : 10.1086/315190

D. Clercq and E. , Cidofovir in the treatment of poxvirus infections, Antiviral Research, vol.55, issue.1, pp.1-13, 2002.
DOI : 10.1016/S0166-3542(02)00008-6

D. Clercq and E. , Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections, Clinical Microbiology Reviews, vol.16, issue.4, pp.569-96, 2003.
DOI : 10.1128/CMR.16.4.569-596.2003

D. Silva, F. S. , and W. Lewis, Poxvirus DNA primase, Proceedings of the National Academy of Sciences, vol.104, issue.47, pp.18724-18733, 2007.
DOI : 10.1073/pnas.0709276104

S. Duraffour and R. Snoeck, Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures, Antivir Ther, vol.12, issue.8, pp.1205-1221, 2007.

A. Ferrier-rembert and R. Drillien, Safety, immunogenicity and protective efficacy in mice of a new cell-cultured Lister smallpox vaccine candidate, Vaccine, vol.25, issue.49, pp.8290-8297, 2007.
DOI : 10.1016/j.vaccine.2007.09.050

A. Ferrier and D. Garin, Rapid inactivation of vaccinia virus in suspension and dried on surfaces, Journal of Hospital Infection, vol.57, issue.1, pp.73-82, 2004.
DOI : 10.1016/j.jhin.2004.01.012

A. M. Geddes, The history of smallpox, Clinics in Dermatology, vol.24, issue.3, pp.152-159, 2006.
DOI : 10.1016/j.clindermatol.2005.11.009

K. Ishii and B. Moss, Mapping Interaction Sites of the A20R Protein Component of the Vaccinia Virus DNA Replication Complex, Virology, vol.303, issue.2, pp.232-241, 2002.
DOI : 10.1006/viro.2002.1721

N. Klemperer and W. Mcdonald, The A20R Protein Is a Stoichiometric Component of the Processive Form of Vaccinia Virus DNA Polymerase, Journal of Virology, vol.75, issue.24, pp.12298-307, 2001.
DOI : 10.1128/JVI.75.24.12298-12307.2001

R. S. Kornbluth and D. F. Smee, Mutations in the E9L Polymerase Gene of Cidofovir-Resistant Vaccinia Virus Strain WR Are Associated with the Drug Resistance Phenotype, Antimicrobial Agents and Chemotherapy, vol.50, issue.12, pp.4038-4081, 2006.
DOI : 10.1128/AAC.00380-06

A. Loregian and D. M. Coen, Selective Anti-Cytomegalovirus Compounds Discovered by Screening for Inhibitors of Subunit Interactions of the Viral Polymerase, Chemistry & Biology, vol.13, issue.2, pp.191-200, 2006.
DOI : 10.1016/j.chembiol.2005.12.002

A. Loregian and H. S. Marsden, Protein-protein interactions as targets for antiviral chemotherapy, Reviews in Medical Virology, vol.56, issue.4, pp.239-62, 2002.
DOI : 10.1002/rmv.356

A. Loregian and G. Palu, Disruption of protein-protein interactions: Towards new targets for chemotherapy, Journal of Cellular Physiology, vol.2, issue.3, pp.750-62, 2005.
DOI : 10.1002/jcp.20356

S. Mccraith and T. Holtzman, Genome-wide analysis of vaccinia virus protein-protein interactions, Proceedings of the National Academy of Sciences, vol.97, issue.9, pp.4879-84, 2000.
DOI : 10.1073/pnas.080078197

B. Moss, D. M. Virology, P. M. Knipe, and . Howley, Poxviridae: The viruses and Their Replication, pp.2905-2945, 2007.

B. W. Nieuwenhuijsen and Y. Huang, A Dual Luciferase Multiplexed High-Throughput Screening Platform for Protein-Protein Interactions, Journal of Biomolecular Screening, vol.8, issue.6, pp.676-84, 2003.
DOI : 10.1177/1087057103258287

S. Parker and E. Touchette, Efficacy of therapeutic intervention with an oral ether???lipid analogue of cidofovir (CMX001) in a lethal mousepox model, Antiviral Research, vol.77, issue.1, pp.39-49, 2008.
DOI : 10.1016/j.antiviral.2007.08.003

B. D. Pilger and C. Cui, Identification of a Small Molecule that Inhibits Herpes Simplex Virus DNA Polymerase Subunit Interactions and Viral Replication, Chemistry & Biology, vol.11, issue.5, pp.647-54, 2004.
DOI : 10.1016/j.chembiol.2004.01.018

N. Scaramozzino and A. Ferrier-rembert, Real-Time PCR to Identify Variola Virus or Other Human Pathogenic Orthopox Viruses, Clinical Chemistry, vol.53, issue.4, pp.606-619, 2007.
DOI : 10.1373/clinchem.2006.068635

D. F. Smee and K. W. Bailey, Treatment of Lethal Vaccinia Virus Respiratory Infections in Mice with Cidofovir, Antiviral Chemistry and Chemotherapy, vol.1, issue.1, pp.71-77, 2001.
DOI : 10.1177/095632020101200105

D. F. Smee and K. W. Bailey, Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice, Antiviral Research, vol.52, issue.1, pp.55-62, 2001.
DOI : 10.1016/S0166-3542(01)00159-0

E. S. Stanitsa and L. Arps, Vaccinia Virus Uracil DNA Glycosylase Interacts with the A20 Protein to Form a Heterodimeric Processivity Factor for the Viral DNA Polymerase, Journal of Biological Chemistry, vol.281, issue.6, pp.3439-51, 2006.
DOI : 10.1074/jbc.M511239200

K. J. Stittelaar and J. Neyts, Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection, Nature, vol.40, issue.7077, pp.745-753, 2006.
DOI : 10.1038/nature04295

G. Yang and D. C. Pevear, An Orally Bioavailable Antipoxvirus Compound (ST-246) Inhibits Extracellular Virus Formation and Protects Mice from Lethal Orthopoxvirus Challenge, Journal of Virology, vol.79, issue.20, pp.13139-13188, 2005.
DOI : 10.1128/JVI.79.20.13139-13149.2005

M. R. Abedi and G. Caponigro, Green fluorescent protein as a scaffold for intracellular presentation of peptides, Nucleic Acids Research, vol.26, issue.2, pp.623-653, 1998.
DOI : 10.1093/nar/26.2.623

K. Alibek, The Soviet Union's Anti-Agricultural Biological Weapons, Annals of the New York Academy of Sciences, vol.894, issue.1 FOOD AND AGRI, pp.18-27, 1999.
DOI : 10.1111/j.1749-6632.1999.tb08038.x

G. Andrei and D. B. Gammon, Cidofovir Resistance in Vaccinia Virus Is Linked to Diminished Virulence in Mice, Journal of Virology, vol.80, issue.19, pp.9391-401, 2006.
DOI : 10.1128/JVI.00605-06

A. Armon-omer and A. Levin, Correlation Between Shiftide Activity and HIV-1 Integrase Inhibition by a Peptide Selected from a Combinatorial Library, Journal of Molecular Biology, vol.376, issue.4, pp.971-82, 2008.
DOI : 10.1016/j.jmb.2007.11.095

A. W. Artenstein and C. Johnson, A novel, cell culture-derived smallpox vaccine in vaccinia-na??ve adults, Vaccine, vol.23, issue.25, pp.3301-3310, 2005.
DOI : 10.1016/j.vaccine.2005.01.079

I. C. Baines and P. Colas, Peptide aptamers as guides for small-molecule drug discovery, Drug Discovery Today, vol.11, issue.7-8, pp.334-375, 2006.
DOI : 10.1016/j.drudis.2006.02.007

J. Balzarini and C. Pannecouque, 6-[2-phosphonomethoxy)alkoxy]-2,4- diaminopyrimidines: a new class of acyclic pyrimidine nucleoside phosphonates with antiviral activity, Nucleosides Nucleotides Nucleic Acids, vol.23, pp.8-9, 2004.

Z. Bengali and A. C. Townsley, Vaccinia virus strain differences in cell attachment and entry, Virology, vol.389, issue.1-2, pp.132-172, 2009.
DOI : 10.1016/j.virol.2009.04.012

P. Berche, The threat of smallpox and bioterrorism, Trends in Microbiology, vol.9, issue.1, pp.15-23, 2001.
DOI : 10.1016/S0966-842X(00)01855-2

R. Blasco and B. Moss, Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein, J Virol, vol.65, issue.11, pp.5910-5930, 1991.

R. Blasco and B. Moss, Role of cell-associated enveloped vaccinia virus in cell-tocell spread, J Virol, vol.66, issue.7, pp.4170-4179, 1992.

J. H. Blum and S. L. Dove, Isolation of peptide aptamers that inhibit intracellular processes, Proceedings of the National Academy of Sciences, vol.97, issue.5, pp.2241-2247, 2000.
DOI : 10.1073/pnas.040573397

M. Bray and M. Martinez, Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir, Antiviral Research, vol.54, issue.3, pp.129-171, 2002.
DOI : 10.1016/S0166-3542(01)00220-0

R. Brent and M. Ptashne, A eukaryotic transcriptional activator bearing the DNA specificity of a prokaryotic repressor, Cell, vol.43, issue.3, pp.729-765, 1985.
DOI : 10.1016/0092-8674(85)90246-6

C. Buerger and K. Nagel-wolfrum, Sequence-specific Peptide Aptamers, Interacting with the Intracellular Domain of the Epidermal Growth Factor Receptor, Interfere with Stat3 Activation and Inhibit the Growth of Tumor Cells, Journal of Biological Chemistry, vol.278, issue.39, pp.37610-37631, 2003.
DOI : 10.1074/jbc.M301629200

R. M. Buller and G. Owens, Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model, Virology, vol.318, issue.2, pp.474-81, 2004.
DOI : 10.1016/j.virol.2003.11.015

K. Butz and C. Denk, Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity, Oncogene, vol.20, issue.45, pp.6579-86, 2001.
DOI : 10.1038/sj.onc.1204805

K. Butz and C. Denk, Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein, Proceedings of the National Academy of Sciences, vol.97, issue.12, pp.6693-6700, 2000.
DOI : 10.1073/pnas.110538897

C. M. Byrd and T. C. Bolken, New Class of Orthopoxvirus Antiviral Drugs That Block Viral Maturation, Journal of Virology, vol.78, issue.22, pp.12147-56, 2004.
DOI : 10.1128/JVI.78.22.12147-12156.2004

C. M. Byrd and D. E. Hruby, Development of an in vitro cleavage assay system to examine vaccinia virus I7L cysteine proteinase activity, Virology Journal, vol.2, issue.1, p.63, 2005.
DOI : 10.1186/1743-422X-2-63

M. D. Challberg and P. T. Englund, The effect of template secondary structure on vaccinia DNA polymerase, J Biol Chem, vol.254, issue.16, pp.7820-7826, 1979.

J. Chantrey and H. Meyer, Cowpox: reservoir hosts and geographic range, Epidemiology and Infection, vol.122, issue.3, pp.455-60, 1999.
DOI : 10.1017/S0950268899002423

C. S. Chung and J. C. Hsiao, A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate, J Virol, vol.72, issue.2, pp.1577-85, 1998.

S. L. Ciesla and J. Trahan, Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney, Antiviral Research, vol.59, issue.3, pp.163-71, 2003.
DOI : 10.1016/S0166-3542(03)00110-4

P. Colas, Combinatorial protein reagents to manipulate protein function, Current Opinion in Chemical Biology, vol.4, issue.1, pp.54-63, 2000.
DOI : 10.1016/S1367-5931(99)00051-4

P. Colas, High-Throughput Screening Assays to Discover Small-Molecule Inhibitors of Protein Interactions, Current Drug Discovery Technologies, vol.5, issue.3, pp.190-199, 2008.
DOI : 10.2174/157016308785739875
URL : https://hal.archives-ouvertes.fr/hal-00416050

P. Colas and B. Cohen, Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2, Nature, vol.380, issue.6574, pp.548-50, 1996.
DOI : 10.1038/380548a0

P. Colas and B. Cohen, Targeted modification and transportation of cellular proteins, Proceedings of the National Academy of Sciences, vol.97, issue.25, pp.13720-13725, 2000.
DOI : 10.1073/pnas.97.25.13720

J. Cono and C. G. Casey, Smallpox vaccination and adverse reactions. Guidance for clinicians, MMWR Recomm Rep, vol.52, issue.4, pp.1-28, 2003.

J. M. Crance and D. Lamarque, Variole : la menace fantôme, Médecine et armées, vol.30, issue.5, pp.495-502, 2002.

C. R. Damaso and J. J. Esposito, An Emergent Poxvirus from Humans and Cattle in Rio de Janeiro State: Cantagalo Virus May Derive from Brazilian Smallpox Vaccine, Virology, vol.277, issue.2, pp.439-488, 2000.
DOI : 10.1006/viro.2000.0603

D. Clercq and E. , Cidofovir in the treatment of poxvirus infections, Antiviral Research, vol.55, issue.1, pp.1-13, 2002.
DOI : 10.1016/S0166-3542(02)00008-6

D. Clercq and E. , The acyclic nucleoside phosphonates from inception to clinical use: Historical perspective, Antiviral Research, vol.75, issue.1, pp.1-13, 2007.
DOI : 10.1016/j.antiviral.2006.10.006

D. Clercq and E. , Acyclic nucleoside phosphonates: Past, present and future, Biochemical Pharmacology, vol.73, issue.7, pp.911-933, 2007.
DOI : 10.1016/j.bcp.2006.09.014

D. Clercq, E. , and A. Holy, A novel selective broad-spectrum anti-DNA virus agent, Nature, vol.28, issue.6087, pp.464-471, 1986.
DOI : 10.1038/323464a0

D. Silva, F. S. , and W. Lewis, Poxvirus DNA primase, Proceedings of the National Academy of Sciences, vol.104, issue.47, pp.18724-18733, 2007.
DOI : 10.1073/pnas.0709276104

D. Silva, F. S. , and B. Moss, Vaccinia Virus Uracil DNA Glycosylase Has an Essential Role in DNA Synthesis That Is Independent of Its Glycosylase Activity: Catalytic Site Mutations Reduce Virulence but Not Virus Replication in Cultured Cells, Journal of Virology, vol.77, issue.1, pp.159-66, 2003.
DOI : 10.1128/JVI.77.1.159-166.2003

L. Deng and P. Dai, Identification of Novel Antipoxviral Agents: Mitoxantrone Inhibits Vaccinia Virus Replication by Blocking Virion Assembly, Journal of Virology, vol.81, issue.24, 2007.
DOI : 10.1128/JVI.00770-07

D. Giulio, D. B. , and P. B. Eckburg, Human monkeypox, The Lancet Infectious Diseases, vol.4, issue.10, p.199, 2004.
DOI : 10.1016/S1473-3099(04)01140-5

I. Drexler and C. Staib, Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?, Current Opinion in Biotechnology, vol.15, issue.6, pp.506-518, 2004.
DOI : 10.1016/j.copbio.2004.09.001

J. Dubochet and M. Adrian, Structure of intracellular mature vaccinia virus observed by cryoelectron microscopy, J Virol, vol.68, issue.3, pp.1935-1976, 1994.

P. L. Earl and E. V. Jones, Homology between DNA polymerases of poxviruses, herpesviruses, and adenoviruses: nucleotide sequence of the vaccinia virus DNA polymerase gene., Proceedings of the National Academy of Sciences, vol.83, issue.11, pp.3659-63, 1986.
DOI : 10.1073/pnas.83.11.3659

J. J. Esposito and F. Fenner, Chapter 85: Poxviruses. Fields Virology Fourth Edition, pp.2885-2921, 2001.

D. Evans and S. Johnson, Electrical protein detection in cell lysates using high-density peptide-aptamer microarrays, Journal of Biology, vol.7, issue.1, p.3, 2008.
DOI : 10.1186/jbiol62

E. Evans and N. Klemperer, The vaccinia virus D5 protein, which is required for DNA replication, is a nucleic acid-independent nucleoside triphosphatase, J Virol, vol.69, issue.9, pp.5353-61, 1995.

E. Evans and P. Traktman, Characterization of vaccinia virus DNA replication mutants with lesions in the D5 gene, Chromosoma, vol.37, issue.S1, pp.72-82, 1992.
DOI : 10.1007/BF02451789

E. Fabbrizio and L. L. Cam, Inhibition of mammalian cell proliferation by genetically selected peptide aptamers that functionally antagonize E2F activity, Oncogene, vol.18, issue.30, pp.4357-63, 1999.
DOI : 10.1038/sj.onc.1202825

F. Fenner, Global Eradication of Smallpox, Clinical Infectious Diseases, vol.4, issue.5, pp.455-460, 1980.
DOI : 10.1093/clinids/4.5.916

F. Fenner and D. A. Henderson, Smallpox and its eradication, 1988.

A. Ferrier-rembert and R. Drillien, Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine, Vaccine, vol.26, issue.14, pp.1794-804, 2008.
DOI : 10.1016/j.vaccine.2007.12.059
URL : https://hal.archives-ouvertes.fr/hal-00282883

A. Ferrier and D. Garin, Rapid inactivation of vaccinia virus in suspension and dried on surfaces, Journal of Hospital Infection, vol.57, issue.1, pp.73-82, 2004.
DOI : 10.1016/j.jhin.2004.01.012

S. Fields and O. Song, A novel genetic system to detect protein???protein interactions, Nature, vol.340, issue.6230, pp.245-251, 1989.
DOI : 10.1038/340245a0

P. E. Fine and Z. Jezek, The Transmission Potential of Monkeypox Virus in Human Populations, International Journal of Epidemiology, vol.17, issue.3, pp.643-50, 1988.
DOI : 10.1093/ije/17.3.643

S. O. Foster and E. W. Brink, Human monkeypox, Bull World Health Organ, vol.46, issue.5, pp.569-76, 1972.

A. M. Geddes, The history of smallpox, Clinics in Dermatology, vol.24, issue.3, pp.152-159, 2006.
DOI : 10.1016/j.clindermatol.2005.11.009

K. Geerinck and G. Lukito, A case of human Orf in an immunocompromised patient treated successfully with cidofovir cream, Journal of Medical Virology, vol.97, issue.4, pp.543-552, 2001.
DOI : 10.1002/jmv.1084

C. R. Geyer and R. Brent, [13] Selection of genetic agents from random peptide aptamer expression libraries, Methods Enzymol, vol.328, pp.171-208, 2000.
DOI : 10.1016/S0076-6879(00)28398-5

R. N. Greenberg and J. S. Kennedy, Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial, The Lancet, vol.365, issue.9457, pp.398-409, 2005.
DOI : 10.1016/S0140-6736(05)70234-8

C. Gubser and S. Hue, Poxvirus genomes: a phylogenetic analysis, Journal of General Virology, vol.85, issue.1, pp.105-122, 2004.
DOI : 10.1099/vir.0.19565-0

E. Guida and A. Bisso, Peptide Aptamers Targeting Mutant p53 Induce Apoptosis in Tumor Cells, Cancer Research, vol.68, issue.16, pp.6550-6558, 2008.
DOI : 10.1158/0008-5472.CAN-08-0137

S. M. Hazel and M. Bennett, A longitudinal study of an endemic disease in its wildlife reservoir: cowpox and wild rodents, Epidemiology and Infection, vol.124, issue.3, pp.551-62, 2000.
DOI : 10.1017/S0950268899003799

J. W. Hooper and D. M. Custer, Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates, Virology, vol.306, issue.1, pp.181-95, 2003.
DOI : 10.1016/S0042-6822(02)00038-7

F. Hoppe-seyler and I. Crnkovic-mertens, Peptide Aptamers: Specific Inhibitors of Protein Function, Current Molecular Medicine, vol.4, issue.5, pp.529-567, 2004.
DOI : 10.2174/1566524043360519

Y. J. Hutin and R. J. Williams, Outbreak of Human Monkeypox, Democratic Republic of Congo, 1996 to 1997, Emerging Infectious Diseases, vol.7, issue.3, pp.434-442, 1996.
DOI : 10.3201/eid0703.017311

V. Ibarra and J. R. Blanco, Efficacy of Cidofovir in the Treatment of Recalcitrant Molluscum Contagiosum in an AIDS Patient, Acta Dermato-Venereologica, vol.80, issue.4, pp.315-321, 2000.
DOI : 10.1080/000155500750012333

K. Ishii and B. Moss, Role of Vaccinia Virus A20R Protein in DNA Replication: Construction and Characterization of Temperature-Sensitive Mutants, Journal of Virology, vol.75, issue.4, pp.1656-63, 2001.
DOI : 10.1128/JVI.75.4.1656-1663.2001

K. Ishii and B. Moss, Mapping Interaction Sites of the A20R Protein Component of the Vaccinia Virus DNA Replication Complex, Virology, vol.303, issue.2, pp.232-241, 2002.
DOI : 10.1006/viro.2002.1721

Z. Jezek and B. Grab, Human monkeypox: disease pattern, incidence and attack rates in a rural area of northern Zaire, Trop Geogr Med, vol.40, issue.2, pp.73-83, 1988.

Z. Jezek and B. Grab, Human monkeypox: secondary attack rates, Bull World Health Organ, vol.66, issue.4, pp.465-70, 1988.

R. Jordan and D. Tien, Single-Dose Safety and Pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor, Antimicrob Agents Chemother, 2008.

J. Kenner and F. Cameron, LC16m8: An attenuated smallpox vaccine, Vaccine, vol.24, issue.47-48, 2006.
DOI : 10.1016/j.vaccine.2006.03.087

E. R. Kern and C. Hartline, Enhanced Inhibition of Orthopoxvirus Replication In Vitro by Alkoxyalkyl Esters of Cidofovir and Cyclic Cidofovir, Antimicrobial Agents and Chemotherapy, vol.46, issue.4, pp.991-996, 2002.
DOI : 10.1128/AAC.46.4.991-995.2002

M. G. Kolonin, R. L. Finley, and J. , Targeting cyclin-dependent kinases in Drosophila with peptide aptamers, Proceedings of the National Academy of Sciences, vol.95, issue.24, pp.95-14266, 1998.
DOI : 10.1073/pnas.95.24.14266

M. G. Kolonin, R. L. Finley, and J. , A Role for Cyclin J in the Rapid Nuclear Division Cycles of Early Drosophila Embryogenesis, Developmental Biology, vol.227, issue.2, pp.661-72, 2000.
DOI : 10.1006/dbio.2000.9916

M. G. Kolonin and J. Zhong, [3] Interaction mating methods in two-hybrid systems, Methods Enzymol, vol.328, pp.26-46, 2000.
DOI : 10.1016/S0076-6879(00)28388-2

M. Krecmerova and A. Holy, )-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine (Cidofovir) and Related Compounds, Journal of Medicinal Chemistry, vol.50, issue.5, pp.1069-77, 2007.
DOI : 10.1021/jm061281+

M. Kretzschmar and J. Wallinga, Frequency of Adverse Events after Vaccination with Different Vaccinia Strains, PLoS Med, vol.3, issue.8, 2006.

S. A. Lacy and M. J. Hitchcock, Effect of Oral Probenecid Coadministration on the Chronic Toxicity and Pharmacokinetics of Intravenous Cidofovir in Cynomolgus Monkeys, Toxicological Sciences, vol.44, issue.2, pp.97-106, 1998.
DOI : 10.1093/toxsci/44.2.97

J. P. Lalezari and B. D. Kuppermann, Clinical Experience With Cidofovir in the Treatment of Cytomegalovirus Retinitis, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol.14, issue.1, pp.27-31, 1997.
DOI : 10.1097/00042560-199700001-00006

J. M. Lane and F. L. Ruben, Complications of Smallpox Vaccination, 1968, New England Journal of Medicine, vol.281, issue.22, pp.1201-1209, 1968.
DOI : 10.1056/NEJM196911272812201

E. R. Lavallie and E. A. Diblasio, A Thioredoxin Gene Fusion Expression System That Circumvents Inclusion Body Formation in the E. coli Cytoplasm, Bio/Technology, vol.230, issue.2, pp.187-93, 1993.
DOI : 10.1038/336690a0

L. Lopez-ochoa and J. Ramirez-prado, Peptide Aptamers That Bind to a Geminivirus Replication Protein Interfere with Viral Replication in Plant Cells, Journal of Virology, vol.80, issue.12, pp.5841-53, 2006.
DOI : 10.1128/JVI.02698-05

A. Loregian and H. S. Marsden, Protein-protein interactions as targets for antiviral chemotherapy, Reviews in Medical Virology, vol.56, issue.4, pp.239-62, 2002.
DOI : 10.1002/rmv.356

A. Loregian and G. Palu, Disruption of protein-protein interactions: Towards new targets for chemotherapy, Journal of Cellular Physiology, vol.2, issue.3, pp.750-62, 2005.
DOI : 10.1002/jcp.20356

Z. Lu and E. R. Lavallie, Using Bio-Panning of FLITRX Peptide Libraries Displayed on E. coli Cell Surface to Study Protein-Protein Interactions, Methods Mol Biol, vol.205, pp.267-80, 2003.
DOI : 10.1385/1-59259-301-1:267

W. C. Magee and K. Y. Hostetler, Mechanism of Inhibition of Vaccinia Virus DNA Polymerase by Cidofovir Diphosphate, Antimicrobial Agents and Chemotherapy, vol.49, issue.8, pp.3153-62, 2005.
DOI : 10.1128/AAC.49.8.3153-3162.2005

B. W. Mahy, An overview on the use of a viral pathogen as a bioterrorism agent: why smallpox?, Antiviral Research, vol.57, issue.1-2, pp.1-5, 2003.
DOI : 10.1016/S0166-3542(02)00194-8

W. F. Mcdonald and P. Traktman, Overexpression and Purification of the Vaccinia Virus DNA Polymerase, Protein Expression and Purification, vol.5, issue.4, pp.409-430, 1994.
DOI : 10.1006/prep.1994.1059

W. F. Mcdonald and P. Traktman, Vaccinia virus DNA polymerase In vitro analysis of parameters affecting processivity, J Biol Chem, vol.269, issue.49, pp.31190-31197, 1994.

A. Mclysaght and P. F. Baldi, Extensive gene gain associated with adaptive evolution of poxviruses, Proceedings of the National Academy of Sciences, vol.100, issue.26, pp.15655-60, 2003.
DOI : 10.1073/pnas.2136653100

K. P. Meadows and S. K. Tyring, Resolution of Recalcitrant Molluscum Contagiosum Virus Lesions in Human Immunodeficiency Virus-Infected Patients Treated With Cidofovir, Archives of Dermatology, vol.133, issue.8, pp.987-90, 1997.
DOI : 10.1001/archderm.1997.03890440061010

A. K. Millns and M. S. Carpenter, The Vaccinia Virus-Encoded Uracil DNA Glycosylase Has an Essential Role in Viral DNA Replication, Virology, vol.198, issue.2, pp.504-517, 1994.
DOI : 10.1006/viro.1994.1061

B. Moss, Chapter 84: Poxviridae: The viruses and their replication. Fields Virology Fourth Edition, pp.2849-2883, 2001.

B. Moss, Chapter 74: Poxviridae: The viruses and their replication. Fields Virology Fourth Edition, pp.2905-2946, 2007.

B. Moss, D. M. Virology, P. M. Knipe, and . Howley, Poxviridae: The viruses and Their Replication, pp.2905-2945, 2007.

K. Nagel-wolfrum and C. Buerger, The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells, Mol Cancer Res, vol.2, issue.3, pp.170-82, 2004.

S. Nauenburg and W. Zwerschke, Induction of apoptosis in cervical carcinoma cells by peptide aptamers that bind to the HPV-16 E7 oncoprotein, The FASEB Journal, vol.15, issue.3, pp.592-596, 2001.
DOI : 10.1096/fj.00-0604fje

J. Neyts and E. De-clercq, Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice, Journal of Medical Virology, vol.139, issue.3, pp.242-248, 1993.
DOI : 10.1002/jmv.1890410312

J. Neyts and E. Verbeken, Effect of 5-Iodo-2'-Deoxyuridine on Vaccinia Virus (Orthopoxvirus) Infections in Mice, Antimicrobial Agents and Chemotherapy, vol.46, issue.9, pp.2842-2849, 2002.
DOI : 10.1128/AAC.46.9.2842-2847.2002

T. C. Norman and D. L. Smith, Genetic Selection of Peptide Inhibitors of Biological Pathways, Science, vol.285, issue.5427, pp.591-596, 1999.
DOI : 10.1126/science.285.5427.591

A. L. Nouvion and J. Thibaut, Modulation of Nr-13 antideath activity by peptide aptamers, Oncogene, vol.275, issue.5, pp.701-711, 2007.
DOI : 10.1038/sj.onc.1209832
URL : https://hal.archives-ouvertes.fr/hal-00314838

L. G. Payne, Significance of Extracellular Enveloped Virus in the in vitro and in vivo Dissemination of Vaccinia, Journal of General Virology, vol.50, issue.1, pp.89-100, 1980.
DOI : 10.1099/0022-1317-50-1-89

A. L. Phelps and A. J. Gates, Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine, Vaccine, vol.25, issue.1, pp.34-42, 2007.
DOI : 10.1016/j.vaccine.2006.07.022

D. Proske and S. Gilch, Prion-Protein-Specific Aptamer Reduces PrPSc Formation, ChemBioChem, vol.3, issue.8, pp.717-742, 2002.
DOI : 10.1002/1439-7633(20020802)3:8<717::AID-CBIC717>3.0.CO;2-C

A. Punjabi and K. Boyle, Clustered Charge-to-Alanine Mutagenesis of the Vaccinia Virus A20 Gene: Temperature-Sensitive Mutants Have a DNA-Minus Phenotype and Are Defective in the Production of Processive DNA Polymerase Activity, Journal of Virology, vol.75, issue.24, pp.12308-12326, 2001.
DOI : 10.1128/JVI.75.24.12308-12318.2001

D. C. Quenelle and R. M. Buller, Efficacy of Delayed Treatment with ST-246 Given Orally against Systemic Orthopoxvirus Infections in Mice, Antimicrobial Agents and Chemotherapy, vol.51, issue.2, pp.689-95, 2007.
DOI : 10.1128/AAC.00879-06

E. Real and J. C. Rain, Antiviral Drug Discovery Strategy Using Combinatorial Libraries of Structurally Constrained Peptides, Journal of Virology, vol.78, issue.14, pp.7410-7417, 2004.
DOI : 10.1128/JVI.78.14.7410-7417.2004
URL : https://hal.archives-ouvertes.fr/pasteur-00177791

P. M. Reeves and B. Bommarius, Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases, Nature Medicine, vol.10, issue.7, pp.731-740, 2005.
DOI : 10.1007/s00705-003-0006-z

S. Schmidt and S. Diriong, Identification of the first Rho-GEF inhibitor, TRIPalpha, which targets the RhoA-specific GEF domain of Trio, FEBS Lett, vol.523, pp.1-3, 2002.

I. W. Sherman, Twelve diseases that changed our world, Emerg Infect Dis, vol.14, issue.5, p.866, 2008.
DOI : 10.1128/9781555816346

D. F. Smee and K. W. Bailey, Treatment of Cowpox Virus Respiratory Infections in Mice with Ribavirin as a Single Agent or Followed Sequentially by Cidofovir, Antiviral Chemistry and Chemotherapy, vol.29, issue.4, pp.303-312, 2000.
DOI : 10.1177/095632020001100406

D. F. Smee and K. W. Bailey, Treatment of lethal cowpox virus respiratory infections in mice with 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine and its orally active diacetate ester prodrug, Antiviral Research, vol.54, issue.2, pp.113-133, 2002.
DOI : 10.1016/S0166-3542(01)00217-0

D. F. Smee and B. L. Hurst, Efficacy of N-methanocarbathymidine in treating mice infected intranasally with the IHD and WR strains of vaccinia virus, Antiviral Research, vol.76, issue.2, pp.124-133, 2007.
DOI : 10.1016/j.antiviral.2007.06.005

G. L. Smith and A. Vanderplasschen, The formation and function of extracellular enveloped vaccinia virus, Journal of General Virology, vol.83, issue.12, pp.2915-2946, 2002.
DOI : 10.1099/0022-1317-83-12-2915

F. Takahashi-nishimaki and K. Suzuki, Genetic Analysis of Vaccinia Virus Lister Strain and Its Attenuated Mutant LC16m8: Production of Intermediate Variants by Homologous Recombination, Journal of General Virology, vol.68, issue.10, pp.2705-2715, 1987.
DOI : 10.1099/0022-1317-68-10-2705

J. P. Vestey and D. L. Yirrell, What Is Human Catpox/Cowpox Infection?, International Journal of Dermatology, vol.124, issue.10, pp.696-704, 1991.
DOI : 10.1016/0140-6736(90)92387-W

V. E. Vichniakov, A study of immunity to smallpox in persons who have experienced a previous attack, Bull World Health Organ, vol.39, issue.3, pp.433-440, 1968.

R. Wittek, Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy, International Journal of Infectious Diseases, vol.10, issue.3, pp.193-201, 2006.
DOI : 10.1016/j.ijid.2005.12.001

R. Woodman and J. T. Yeh, Design and Validation of a Neutral Protein Scaffold for the Presentation of Peptide Aptamers, Journal of Molecular Biology, vol.352, issue.5, pp.1118-1151, 2005.
DOI : 10.1016/j.jmb.2005.08.001

C. W. Xu and Z. Luo, Inactivation of Ras function by allele-specific peptide aptamers, Oncogene, vol.21, issue.37, pp.5753-5760, 2002.
DOI : 10.1038/sj.onc.1205680

C. W. Xu and A. R. Mendelsohn, Cells that register logical relationships among proteins, Proceedings of the National Academy of Sciences, vol.94, issue.23, pp.12473-12481, 1997.
DOI : 10.1073/pnas.94.23.12473

H. Yang and S. K. Kim, Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction, Journal of Clinical Investigation, vol.115, issue.2, pp.379-87, 2005.
DOI : 10.1172/JCI23220DS1